Drug Profile
EYN 1601
Latest Information Update: 22 Feb 2022
Price :
$50
*
At a glance
- Originator Eyenovia
- Class
- Mechanism of Action
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Mydriasis
Most Recent Events
- 22 Feb 2022 Discontinued - Phase-II for Mydriasis (In volunteers) in USA (Ophthalmic) (Eyenovia pipeline, February 2022)
- 05 Jun 2018 Eyenovia receives patent allowances for micro-therapeutic ophthalmic delivery system in USA
- 01 Nov 2016 Eyenovia completes a phase-II clinical trial in Mydriasis (In volunteers) in USA (Ophthalmic) (NCT02946125)